External applicability of SGLT2 inhibitor cardiovascular outcome trials to patients with type 2 diabetes and cardiovascular disease.

Lisanne C A SmidtFrank L J VisserenWendela L de Ranitz-GrevenHendrik M NathoeL Jaap KappelleGert J de BorstHarold W de ValkJan Westerinknull null

Published in: Cardiovascular diabetology (2021)

A large proportion of patients with type 2 diabetes and cardiovascular disease in daily clinical practice would have been eligible for participation in the SGLT2i CVOTs. Trial eligible and ineligible patients have the same risk for MACE and all-cause mortality.

Keyphrases

cardiovascular disease
end stage renal disease
clinical practice
physical activity
newly diagnosed
ejection fraction
chronic kidney disease
type diabetes
clinical trial
prognostic factors
study protocol
metabolic syndrome
phase iii
patient reported outcomes
phase ii
coronary artery disease
open label
double blind